AbbVie Inc (ABBV) : Baird Financial Group scooped up 64,610 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 2,238,349 shares of AbbVie Inc which is valued at $138.8 Million.AbbVie Inc makes up approximately 1.34% of Baird Financial Group’s portfolio.
Other Hedge Funds, Including , Kings Point Capital Management sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 885 shares of ABBV which is valued $54,870.Baldwin Investment Management reduced its stake in ABBV by selling 3 shares or 0.02% in the most recent quarter. The Hedge Fund company now holds 19,935 shares of ABBV which is valued at $1.2 Million. AbbVie Inc makes up approx 0.54% of Baldwin Investment Management’s portfolio.Hedeker Wealth Management Group boosted its stake in ABBV in the latest quarter, The investment management firm added 276 additional shares and now holds a total of 29,078 shares of AbbVie Inc which is valued at $1.8 Million. AbbVie Inc makes up approx 1.70% of Hedeker Wealth Management Group’s portfolio.Sonora Investment Management reduced its stake in ABBV by selling 103 shares or 22.69% in the most recent quarter. The Hedge Fund company now holds 351 shares of ABBV which is valued at $21,762. AbbVie Inc makes up approx 0.01% of Sonora Investment Management’s portfolio.First National Bank Sioux Falls reduced its stake in ABBV by selling 90 shares or 2.24% in the most recent quarter. The Hedge Fund company now holds 3,927 shares of ABBV which is valued at $245,477. AbbVie Inc makes up approx 0.82% of First National Bank Sioux Falls’s portfolio.
AbbVie Inc opened for trading at $59.63 and hit $60.05 on the upside on Friday, eventually ending the session at $59.69, with a gain of 0.69% or 0.41 points. The heightened volatility saw the trading volume jump to 1,12,59,353 shares. Company has a market cap of $96,540 M.
On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.